A double-blind, controlled vs placebo trial to evaluate the efficacy of EPA and DHA ethyl esters, in addition to usual antiarrhythmic therapy, in the manintenance of synus rythm in patients candidate to electrical cardioversion of persistent atrial fibrillation.
Phase of Trial: Phase III
Latest Information Update: 25 May 2011
At a glance
- Drugs Omega-3-acid ethyl esters (Primary) ; Antiarrhythmics
- Indications Atrial fibrillation
- Focus Therapeutic Use
- 25 May 2011 New trial record